[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"degenerative-mitral-valve-regurgitation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:degenerative-mitral-valve-regurgitation":39},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":4,"eligibilityCriteria":13,"healthyVolunteers":10,"sex":14,"minAge":15,"maxAge":4,"enrollmentInfo":16,"targetDuration":4,"studyType":19,"phases":20,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":5},"100578662",false,"NCT06814210","CAP-TEER: CerebrAl Protection During Transcatheter Edge-to-edge Repair","Inclusion Criteria:\n\nSubjects must meet ALL of the following criteria:\n\nGeneral Inclusion Criteria\n\n* Age ≥18 years\n* Severe Mitral Regurgitation (3+ to 4+)\n* Symptom status: NYHA functional class ≥ II\n* Subjects scheduled to receive the M-TEER per the current approved indications for use\n* Subjects agreed to join the study and complete follow-up\n\nExclusion Criteria:\n\nPotential Subjects will be excluded if ANY of the following criteria apply:\n\nGeneral Exclusion Criteria\n\n* Contraindication to MRI\n* CABG, PCI, TAVR, CRT or CRT-D within the prior 30 days\n* Aortic or tricuspid valve disease requiring surgery or transcatheter intervention\n* COPD requiring continuous home oxygen therapy or chronic outpatient oral steroid use\n* Cerebrovascular accident within prior 30 days\n* Severe symptomatic carotid stenosis (\\>70% by ultrasound)\n* Carotid surgery or stenting within prior 30 days\n* Hemodynamic instability requiring inotropic support or mechanical heart assistance\n* Need for emergent or urgent surgery for any reason or any planned cardiac surgery within the next 12 months.\n* Contraindication for transesophageal echocardiography\n* Life expectancy \\\u003C 1 year\n* Pregnant or planning pregnancy within next 12 months\n* Participation in another interventional Trial\n* Patients who are not able to give consent or complete the follow-up","ALL","18 Years",{"count":17,"type":18},120,"ESTIMATED","INTERVENTIONAL",[21],"NA","Transcatheter edge-to-edge repair of the mitral valve (M-TEER) is a well-established endovascular treatment option for patients with severe mitral regurgitation who are at high risk for surgery-related complications. However, the procedure carries a risk of clinically overt strokes and imaging-detected brain lesions, which may potentially be mitigated through the use of cerebral protection devices.\n\nThis prospective, multi-center, randomized, controlled study aims to assess the efficacy and safety of cerebral protection device, compared to a control group undergoing unprotected M-TEER.",[24,25,26],"Mitral Regurgitation","Functional Mitral Regurgitation","Degenerative Mitral Valve Regurgitation","NOT_YET_RECRUITING","2025-02-05",{"date":30,"type":31},"2025-02-07","ACTUAL",{"date":33,"type":18},"2025-03-01",{"date":35,"type":18},"2025-10-31",{"name":37,"class":38},"Xiao-dong Zhuang","OTHER",""]